An independent data monitoring committee concluded a Phase 3 study of Arcus and Gilead’s anti‑TIGIT antibody domvanalimab would not meet its endpoints, prompting the partners to halt the upper‑GI trial and to cancel related combination studies. Arcus said it will reprioritize R&D and wind down select domvanalimab programs. The failure adds to a string of recent clinical setbacks for TIGIT as a target and is prompting sponsors to reassess development plans for immune‑checkpoint combinations. Arcus said leaders will redeploy resources to other oncology assets and that ongoing collaboration terms with Gilead remain in effect for defined programs. Investors and immuno-oncology researchers noted the outcome narrows near‑term clinical options for TIGIT inhibitors and could reallocate capital toward other immunotherapy modalities.